CDT Equity (NASDAQ:CDT) Announces Earnings Results

by · The Markets Daily

CDT Equity (NASDAQ:CDT – Get Free Report) issued its quarterly earnings results on Wednesday. The company reported ($8.71) earnings per share (EPS) for the quarter, Zacks reports.

CDT Equity Stock Down 1.0%

CDT Equity stock traded down $0.03 on Wednesday, hitting $2.93. The company’s stock had a trading volume of 18,708 shares, compared to its average volume of 299,725. CDT Equity has a one year low of $2.53 and a one year high of $3,700.00. The firm has a market cap of $1.85 million, a P/E ratio of -0.00 and a beta of 1.52. The company has a fifty day moving average price of $5.43 and a 200-day moving average price of $78.79.

Analyst Ratings Changes

A number of research firms have issued reports on CDT. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CDT Equity in a report on Wednesday, June 24th. Wall Street Zen upgraded shares of CDT Equity from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

View Our Latest Stock Report on CDT Equity

CDT Equity Company Profile

(Get Free Report)

Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.

Featured Stories